Evidence map›Paper›PMID 35162953›Full record

ArticleInternational journal of molecular sciences2022

Common T-Cell-Receptor Motifs and Features in Patients with Cytomegalovirus (CMV)-Seronegative End-Stage Renal Disease Receiving a Peptide Vaccination against CMV.

Lukas Bunse, Claudia Sommerer, Chin Leng Tan, Felix Korell, Anita Schmitt, Angela Hückelhoven-Krauss, Brigitte Neuber, Thomas Mertens, Michael Platten, Edward W Green and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Lukas BunseDKTK CCU Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.ORCID 0000-0002-4490-7574
Claudia SommererDivision of Nephrology, University Hospital Heidelberg, Renal Clinic Heidelberg, 69120 Heidelberg, Germany.
Chin Leng TanDKTK CCU Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
Felix KorellDepartment of Internal Medicine V, University Hospital Heidelberg, 69120 Heidelberg, Germany.ORCID 0000-0001-7699-7212
Anita SchmittDepartment of Internal Medicine V, University Hospital Heidelberg, 69120 Heidelberg, Germany.
Angela Hückelhoven-KraussDepartment of Internal Medicine V, University Hospital Heidelberg, 69120 Heidelberg, Germany.
Brigitte NeuberDepartment of Internal Medicine V, University Hospital Heidelberg, 69120 Heidelberg, Germany.
Thomas MertensInstitute of Virology, University of Ulm, 89081 Ulm, Germany.
Michael PlattenDKTK CCU Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.ORCID 0000-0002-4746-887X
Edward W GreenDKTK CCU Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
Martin ZeierDivision of Nephrology, University Hospital Heidelberg, Renal Clinic Heidelberg, 69120 Heidelberg, Germany.
Michael SchmittDepartment of Internal Medicine V, University Hospital Heidelberg, 69120 Heidelberg, Germany.ORCID 0000-0002-1579-1509
Heidelberg University · DEGerman Cancer Research Center · DEUniversität Ulm · DE

Funding

Baden-Württemberg Stiftung (Michael Platten) BWST_ISF2018-046Else Kröner-Fresenius Foundation (EKMS) and Deutsche Forschungsgemeinschaft, (Lukas Bunse) SFB 1389-B03The CMVPepVac Study Scientific Committee designed the study, reviewed the study data and statistical analysis, and wrote the report. All authors had full access to the study data, decided to submit the report for publication, assume responsibility for the SFB 1389-B03
6 · The paper itself

Abstract

After solid-organ transplantation, reactivation of the cytomegalovirus (CMV) is often observed in seronegative patients and associated with a high risk of disease and mortality. CMV-specific T cells can prevent CMV reactivation. In a phase 1 trial, CMV-seronegative patients with end-stage renal disease listed for kidney transplantation were subjected to CMV phosphoprotein 65 (CMVpp65) peptide vaccination and further investigated for T-cell responses. To this end, CMV-specific CD8

Indexed as

CD8-Positive T-LymphocytesClinical Trials, Phase I as TopicCytomegalovirusCytomegalovirus InfectionsCytomegalovirus VaccinesHumansKidney Failure, ChronicKidney TransplantationReceptors, Antigen, T-CellSequence Analysis, RNASingle Molecule ImagingViral Matrix Proteinscytomegalovirus matrix protein 65kDaCytomegalovirus VaccinesReceptors, Antigen, T-CellViral Matrix ProteinsCMVend-stage renal diseasepeptide vaccinationsingle-cell sequencingTCR motif

Identifiers

PMID35162953
PMCPMC8835207
OpenAlexW4205613507

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.